...held the option under an amended 2013 deal. Created in 2012 by MPM Capital as Mitokyne Inc....

...million in milestones under an amended 2013 deal. Created in 2012 by MPM Capital as Mitokyne Inc....
...The deal is expected to close in the next several weeks. Jaime De Leon MA-0211 MA-0217 MTB-1 MTB-2 Astellas Pharma Inc. Mitobridge Inc. Mitokyne Inc. MPM...

...basic research and creation of drug-like molecules,” he said. Mitobridge was created by MPM as Mitokyne Inc....

...expects to begin a trial in ambulatory DMD patients next year. In 2013, Mitobridge (formerly Mitokyne Inc....

...Astellas also said it would explore muscle diseases in partnership with Mitobridge Inc. (formerly Mitokyne...

...Astellas and MPM participated in a $45 million series A round for Mitobridge Inc. (then Mitokyne Inc....

...commercial milestones and royalties (see BioCentury, May 5, 2008) . In 2013, Astellas partnered with MitoKyne Inc....

...mitochondrial activity to treat neuromuscular, cardiovascular and metabolic diseases, starting with Orphan or hereditary indications. Mitokyne...
...and former CEO of Epizyme Inc. Shiosaki is managing partner at MPM Capital, which seeded Mitokyne...
...$45 million series A round last October. Under a deal with Astellas Pharma Inc. , Mitokyne...

...delivering payloads into the mitochondria. Partikula is not the only company focused on mitochondria, however. Mitokyne Inc....
...neurodegenerative disorders as well as aging diseases. Details about Mitokyne's technology are undisclosed. Last year, Mitokyne...
...for up to $730 million. Companies and Institutions Mentioned Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Mitokyne Inc....